Tag Archives: stroke

NOW: NOTICE OF CLASS ACTION SETTLEMENT FOR VIOXX

Merck's Super Aspirin

9 Years after the recall of the drug Vioxx some of the Canadian victims will be compensated by a class action settlement.

 

VIOXX CLASS ACTION SETTLEMENT CANADA NOW BEING IMPLEMENTED. FILING CLAIMS OPENED APRIL 20, 2013

THE COURTS OF ALL PROVINCES APPROVED THE VIOXX SETTLEMENT FOR ENFORCEMENT AND NOTICE HAS BEEN PUBLISHED  THAT WE WILL BE ABLE TO SUBMIT CLAIMS TO THE CLAIMS ADMINISTRATOR FROM SATURDAY APRIL 20 TO MONDAY AUGUST 19, 2013.  NOTICE WAS PUBLISHED IN MAJOR NEWSPAPERS ACROSS CANADA ON SATURDAY APRIL 20TH. THIS FOLLOWS THE MAIN SETTLEMENT APPROVALS WHICH TOOK PLACE IN 2012.  DETAILS ARE AS FOLLOWS:

In the summer of 2012 a settlement of Vioxx injury claims in Canada was presented for approval to courts in Ontario, Saskatchewan and then Quebec.  The courts were asked by lawyers for Merck and lawyers for the class action to approve a settlement that was negotiated in 2011 and announced in January 2012. For background information, settlement details and events leading up to settlement approval please read our earlier posts.

The courts were asked to either accept or reject the negotiated agreement and also approve the fees and expenses to be paid from the settlement to the consortium of law firms across Canada who were involved in the class action proceedings.  There was no jurisdiction to change the terms of settlement.  In a decision released September 18, 2012 Madam Justice Leitch of Ontario’s Superior Court of Justice approved the settlement and approved the fees, taxes and disbursements of the class action lawyers.  A similar approval decision was issued by Justice Marcotte of the Quebec Superior Court on October 4, 2012. Justice Currie of the Saskatchewan Court of the Queens Bench also gave approval but without issuing reasons on July 25, 2012.

The settlement as approved provides for the following payments to be made by the drug manufacturer Merck:

1.  $3,500,000 to be paid to Canada’s provincial health insurers to reimburse medical expenses of Vioxx victims.

2.  $1,000,000 to be paid for the cost of notices and claims administration.

3.  $6,000,000 to be paid to the class action lawyers allocated as approximately $4,500,000 for legal fees, $1,000,000 for expenses and $500,000 for GST and provincial taxes applicable to the legal fees.  This does not include any money for the lawyers representing individual claimants who will be paid from the money available to pay actual claims of Vioxx victims.

4.  $22,612,500 to be paid to Vioxx victims who are eligible for payment under the settlement.  That amount will be increased if there are over 1,500 such people to a maximum of $26,381,250. Most claimants will pay their own lawyers a percentage of their recovery for legal fees, taxes and expenses none of which are provided for in the settlement.

To be eligible for payment under the settlement a person must pass both the “usage gate” and the “event gate”.  The usage gate requires a certain amount of Vioxx to be consumed in the time immediately before the event.  The event gate requires a person claiming to have had a heart attack, sudden cardiac death or an ischemic stroke.  Stroke victims will be given $5,000 compensation regardless of the severity of the stroke or its lasting effects.  It is estimated for those with heart attack or sudden cardiac death, that after deductions for various risk factors (other than Vioxx use) and after legal costs the average person will receive $15,000 to $25,000 compensation.  That means some will receive more  and some will receive less.  The maximum in the best case would be about $100,000 before legal fees.  There is also payment to spouses and children (including adult children) of victims which is additional money up to 20% of what is paid to the principal claimant.  In every case certain medical and pharmacy records are required to prove use, show other risk factors and prove that there is a qualifying event.  The cost of obtaining records is an expense that is to be paid from the compensation received. As well most claimants will pay from the compensation legal fees averaging one third of the compensation paid.  They will also pay provincial and federal tax (PST, HST, GST) on the legal fees.  There is no income tax payable on the net compensation that victims and their families will actually receive.

The compensation being paid to Vioxx victims is clearly quite low in relation to the seriousness of having had a heart attack, stroke or sudden cardiac death.  The court considered that these events are common in Canada among persons who have not used Vioxx and that use of Vioxx is not necessarily the cause of the event.  They considered expert medical opinion on Vioxx’s role in causation noting that the connection to stroke is not as clearly proven as the connection to heart attack.  They accepted that persons with other conditions not covered by the settlement were a minority in the class and that it was reasonable and in the best interests of the class as a whole to accept a settlement that did not compensate them. The courts considered the continuing denial by Merck of any liability and the risk of the case not succeeding if the settlement was not approved.  They did consider the negative result in the Australian court and the fact that cases tried in the US had mixed results.  It was noted that even if the case proceeded to trial successfully payment of claims could be delayed by appeals. The court decided that the settlement is in the best interests of the class members.

The approval decisions had to be confirmed for enforcement purposes in the courts of all other Provinces.  This had to be completed before any claims for Vioxx victims can be submitted for processing to the class action administrator.  The Miskin law office is now submitting Vioxx claims for processing and payment.  We have been in contact with the class action administrators who will be receiving claims for compensation and processing them.  On April 20th there will be national advertising of the settlement and the claims processing will then begin. We are sending claim forms to clients to sign and also have signed by family members who are eligible for compensation.  This was expected to happen some time in January 2013 but due to delays in Provincial enforcement approval it took until March to get all the Provincial court orders and we now know that April 20 is the first day to begin to submit claims for processing. There is a period of four months open for submission of claims. At the end of that period assessment notices will be sent out by the claims administrator for every claim filed and payment of Canadian Vioxx claims will finally begin. If you believe you have a claim and have a lawyer make sure they have everything they need to file the claim.  If you do not yet have a lawyer you really should get one immediately to ensure you have everything you need in time to make a claim. Our office is still accepting new clients who qualify under the settlement but it is necessary to fully document claims which makes it difficult if you have not started to document a claim. It is essential to move quickly to have sufficient information in time to file a successful claim.

Yaz and Yasmin Claims Class Action Certification

Lawsuits Against Bayer

Bayer’s Birth Control Products

 

 

Many individual law suits in the USA  and Canadian Class Action lawsuits are in progress over the side effects of the two similar birth control pills Yaz and Yasmin. Serious side effects include deep vein thrombosis, pulmonary embolism and very commonly loss of the gallbladder.   Those cases are being fought by the manufacturer Bayer in different US districts where they are co-ordinated in Multi District Litigation (MDLs). The courts in Illinois and Pennsylvania ordered  mediation to take place before cases were to go to trial in early 2012. In the mediation process Bayer agreed in early March 2012 to a settlement in 70  lawsuits.  There are now as many as 3500 settlements of the most serious cases involving deep vein thrombosis or pulmonary embolism in the USA in the range of $200,000 each.  Until recently there was no settlement for gallbladder cases but they are now beginning to settle for much less.  Gallbladder cases are settling in the range of a few thousand dollars.  Also in Canada settlements are generally much lower than they are in the US and so expectations on all cases should be lower.  The earlier settlements were only for women who took Yaz or Yasmin and suffered deep vein thrombosis (blood clots) or a pulmonary embolism.  We are hopeful that some progress will be made towards resolving claims in Canada after there is certification of the Canadian Yaz and Yasmin Class Action lawsuit.  We are hoping they will settle gallbladder cases as well as deep vein thrombosis and pulmonary embolism cases as part of the likely future class action settlement. The greatest number of claims relate to gallbladder where nominal settlements should be expected in Canada.   The pills continue to be sold and to be very profitable for Bayer.  A recommendation to recall the drug was narrowly defeated by an advisory committee to the US Food and Drug Administration (FDA).  Bayer has changed its advertisements and product warnings since then.  THE CLASS ACTION HAS NOW BEEN LIMITED TO CLAIMS FOR INCIDENTS UP TO NOVEMBER 30, 2011 SO IF YOU HAVE A PROBLEM THAT CAME UP AFTER THAT DATE IT IS NOT INCLUDED IN THE CLASS ACTION AND IT WOULD BE GOOD TO CONTACT A LAWYER IMMEDIATELY TO PROTECT YOUR RIGHTS.  

Yaz or Yasmin can cause dehydration which causes an increase in the potassium levels (hyperkalemia) and a decrease in the sodium levels (hyponatremia) in the body.  As potassium acts as a key control in cardiac rhythm, this imbalance can cause hyperkalemia arrhythmias, which, in turn can cause blood clots and thrombotic events such as stroke or deep vein thrombosis, pulmonary embolism, or heart attack. Dehydration is also a risk factor for kidney stones and gallbladder disease. While other birth control pills can also cause deep vein thrombosis and other thrombotic events, the cause of those effects are from the estrogen side of the equation. The thrombotic effects of Yaz and Yasmin are from the progesterin side. While it has long been accepted that high estrogen levels can cause these adverse events, the birth control pills Yaz, Yasmin and Ocella have been marketed as having low estrogen levels, thereby having a lower risk for thrombotic events. There have been several studies that have called this into question.
The Miskin Law firm is making claims related to these oral contraceptive drugs and working with the class action court proceedings that have been started in Canada. These proceedings take a long time to advance and they stop individual law suits from proceeding for now. An application for certification of the class action was heard in the Ontario court in late January 2013 before Justice D.S. Crane.  A formal decision has not yet been made but on April 15, 2013 the judge released reasons for decision where he rejected arguments against certifying the class action.  He expressed concern over the proposed timetable for proceedings and there will be further discussion before a formal certification order is actually given.  It is expected that a court order of certification of the class action will issue soon.  Until then we are working to document our clients’ claims and we are being retained by new clients.  We represent people to get them compensation both individually and through the class action process. Once there is certification by the court of the class action people will have a choice of claiming through it or trying to get more with special circumstances in an individual claim and we will explain that option to each of our clients. Contact us if you believe you have been harmed by Yaz or Yasmin. Email Murray Miskin directly: miskinlaw@yahoo.com

Celebrex Class Action Lawsuit Settlement Compared

Bextra - Worse than Vioxx

Bextra from Pfizer

 

 

PLEASE BE AWARE THAT THE DEADLINE FOR SUBMITTING CELEBREX OR BEXTRA CLAIMS PASSED ON DECEMBER 20, 2012

Pfizer’s Cox 2 inhibitor drug Celebrex is similar to Merck’s Vioxx and Pfizer’s more powerful version Bextra.  Celebrex remains on the market and Bextra was banned soon after Vioxx in 2004.  While Merck’s equivalent drug Vioxx was the most hotly contested and publicized lawsuit for this type of drug which can trigger heart attacks and ischemic strokes, class action lawsuits proceeded quietly including a Canadian Class Action lawsuit covering both Pfizer products. Celebrex statistically appears to have less problems than the other drugs and for that reason it has been allowed to remain in use. Celebrex compensation is limited to those who were prescribed the drug before 2006 when warnings became stronger.

Both the Merck and Pfizer class action lawsuit settlements include a maximum compensation of $100,000 as base compensation plus an amount for the victim’s family members.  For the Vioxx settlement, stroke compensation is to a maximum of $5000 while that limit does not apply to the Pfizer class action lawsuit settlement.  The case against Pfizer settled sooner and on a more generous basis which includes additional compensation for loss of income and for “consumer costs” which are the costs of the medication purchased by claimants. In the Vioxx settlement there are reductions in compensation based on numerous other risk factors that in most cases will greatly reduce what is paid.  For Bextra and Celebrex the level of compensation is mainly determined by the dosage with lower dosage use claimant limited to $25,000 base compensation. The settlement in Vioxx cases is restricted  to cardiovascular conditions and only covers heart attack, ischemic stroke and sudden cardiac death.  The Pfizer class action lawsuit settlement includes up to $10,000 as a base amount for “other cardiac, renal or vascular event”.  That means less people will be excluded from compensation under that settlement than with the Vioxx settlement.
The Vioxx class action lawsuit settlement totaling about $37 million is triple the amount of dollars as the Pfizer settlement, but there are many more claimants for Vioxx.  Court approval hearings are complete for the Vioxx settlement and we have received the Judges’ decision on approval of the settlement. The total of the Pfizer settlement is twelve million dollars.  The Pfizer settlement has also been given court approval several months ago and we have submitted applications for compensation for individual clients.  Those applications are now being processed and we are waiting for compensation decisions. Bextra has been known to cause severe skin reactions including a horrible and rare condition called Stevens Johnson Syndrome (SJS) and it is compensated too.  If you believe you or a family member may qualify for compensation for any of these drugs please call our office or email: miskinlaw@yahoo.com   The claim process is best handled with legal assistance which we can provide on a contingency fee basis. That means we do not charge a fee or any expenses until and unless we get you compensation on your claim.

For details of the Vioxx settlement and court approval information read our main Vioxx page. For official information on the settlement of Pfizer claim refer to: http://www.bextracelebrexsettlement-en.ca/index.html

Merck Vioxx Class Action Settlement Court Approval

Merck’s Super Aspirin was Vioxx

THIS IS AN APRIL 20, 2013 UPDATE OF INFORMATION ABOUT COURT APPROVAL OF THE SETTLEMENT OF THE CANADIAN VIOXX CLASS ACTION NEGOTIATED WITH MERCK BY THE CANADIAN CLASS ACTION LAW FIRMS AND ANNOUNCED OVER A YEAR AGO IN JANUARY 2012. THE SETTLEMENT WAS CONDITIONAL ON COURT APPROVAL AFTER CONSIDERING THE FAIRNESS OF THE TERMS OF SETTLEMENT. FAIRNESS HEARINGS HAVE BEEN HELD IN ONTARIO FOR ALL OF CANADA, EXCEPT SASKATCHEWAN (WHICH HELD A HEARING FOR SASKATCHEWAN JULY 25) AND QUEBEC WHOSE HEARING WAS ON SEPTEMBER 7TH. FINAL COURT APPROVAL OF THE SETTLEMENT WAS GIVEN BY EACH COURT. THERE WAS NOT ENOUGH OF A CASE AGAINST THE SETTLEMENT BROUGHT TO THE COURT TO FORM A BASIS FOR TURNING DOWN THE SETTLEMENT.  THE THREE JUDGES CONSULTED EACH OTHER TO ENSURE CONSISTENCY IN THE THEIR DECISIONS AND REASONS.

The remainder of this post has only been partially updated to note the completion of settlement approval.  For the latest information go to our new web page after reading this.

OUR LAW FIRM, WHICH REPRESENTS OVER 300 VIOXX CLAIMANTS, IS BASED IN ONTARIO AND MURRAY MISKIN ATTENDED THE ONTARIO HEARING ONLY. THE FAIRNESS HEARING IN ONTARIO WAS HELD AT THE LONDON COURTHOUSE 80 DUNDAS STREET ON TUESDAY JULY 17TH AT 10 AM BEFORE MADAM JUSTICE LEITCH OF  THE ONTARIO SUPERIOR COURT. HER HONOUR INDICATED SHE WILL PREPARE A DECISION TO BE RELEASED AFTER CONSULTATION WITH THE SASKATCHEWAN AND QUEBEC JUDGES HEARING THE SAME MOTION.  AT THE HEARING SUBMISSIONS WERE MADE BY MICHAEL PEERLESS OF THE SISKINDS  LAW FIRM ON BEHALF OF THE CLASS ACTION PLAINTIFFS AND BY KATHERINE BEAGAN FLOOD ON BEHALF OF MERCK WITH TWO PEOPLE SPEAKING AGAINST THE SETTLEMENT INCLUDING GARY ROBERTS THE HUSBAND OF ONE OF OUR CLIENTS WHO IS NOT ENTITLED TO COMPENSATION UNDER THE SETTLEMENT.  THE OTHER PERSON SPEAKING WAS MRS. DUFOUR WHO STOPPED USING VIOXX A FEW MONTHS BEFORE HER HEART ATTACK AND WHO WOULD NOT QUALIFY UNDER THE SETTLEMENT. MURRAY MISKIN WHO CAME TO OBSERVE THE PROCEEDINGS WAS ASKED BY THE COURT TO SPEAK AND DID SO ON BEHALF OF HIS CLIENTS SOME OF WHOM SUPPORT AND SOME OF WHOM OPPOSE THE SETTLEMENT.

THE ONTARIO HEARING APPLIED TO ALL CLAIMS EXCEPT THOSE IN QUEBEC AND SASKATCHEWAN. ORDERS HAVE BEEN MADE IN ALL PROVINCES SETTING OUT THE APPROVAL PROCESS REQUIREMENTS. THE FOLLOWING IS A LINK TO THE ONTARIO COURT ORDER SETTING OUT INFORMATION ABOUT THE SETTLEMENT AND THE APPROVAL PROCESS: ONTARIO COURT

The settlement was announced in January 2012 with much attention by the media but there has been almost none since then.  Notices were posted in newspapers nationally about the court dates on June 9, 2012. Everyone who is affected had a right to be heard on this and the settlement is only to be approved by the court if it is believed to be in the best interests of Vioxx victims.  There has been no media coverage of the settlement approval process and this website has been the only source of information on what has happened and what has  happened until now.  There are now official notices and more information at vioxxclassaction.ca

 The following information about Vioxx and the settlement was published in this website’s post before the court approval dates:

Merck’s once popular anti-inflammatory drug Vioxx turned out to be a deadly drug for many people. It was voluntarily withdrawn and then recalled in 2004 with numerous lawsuits that followed, including, in Canada, a Class Action claim which took precedence over possible individual claims under Canadian law. Merck fought claims world wide settling in the USA only after a few years.  Our firm brought some claims in the New Jersey court working with US lawyers on the cases.  When the US case settled in November 2007 it was a term of settlement that all foreign claimants cases had to be dropped by the US lawyers.  At that point the judge handling the case had already ruled that British claimants should proceed in the court of their own country and we were expecting a similar decision for Canadians.  We then had no choice but to wait for the Canadian class action which had been delayed by arguments between lawyers over which law firm would manage the case and then by Merck’s procedural delays and appeals.  When the Canadian case was finally certified to proceed with no further right to appeal some of our clients with stronger cases chose to opt out of the class action so they could make individual claims hoping for better settlements.

In Australia last year Merck did well after a major test case trial which found liability only in heart attack situations and specifically concluded after much expert evidence that there is no proof that Vioxx causes strokes or other cardiovascular problems. The Judge ordered compensation in a heart attack case but that was overturned on appeal by Merck.  The negative finding in stroke cases was not even appealed as the evidence was clearly not enough for proof.  It was after the Australian case victory that Merck was ready to negotiate with the Canadian Class Action lawyers.  The negotiations conducted on behalf of all persons in Canada claiming, resulted in a settlement agreement announced January 19, 2012.  There is a national Vioxx settlement in Canada.  The amount of the settlement is proportionately much less than the US settlement on a per capita basis.  It provides compensation up to $100,000 in heart attack and sudden cardiac death cases and pays an amount capped at $5,000 in ischemic stroke cases.  Stroke compensation does not include payment for Transient Ischemic Attacks (TIA). Nothing is paid in the settlement for hemorrhagic strokes or other conditions. This settlement was negotiated with Merck by the Class Action lawyers not the law firms (like ours) representing individual clients. When a settlement agreement was reached by the negotiators it asked for persons who had opted out of the Class Action to agree to opt back in and accept the settlement.  This happened as all the clients now represented by Canadian lawyers who had opted out agreed to accept the settlement. Our opted out clients were not prepared to take the high risk of proceeding with their own individual cases in court. Those who had not opted out of the Class Action were not given a choice.  Our firm acts for a large number of individual clients, and we are determining how each of our clients will benefit (or not) from the settlement). It is a complex settlement factoring dates of use in relation to the cardiac event and with numerous reductions based on risk factors. We have written letters to most of our clients who do not qualify for compensation under the settlement to advise them of their rights.  We have written to others where we need additional information to determine if they will be compensated and for some we are still trying to determine if there is eligibility. We are preparing and sending out actual claim forms to our clients and family members for signature.  We are now submitting claims where the documentation is complete with forms all signed.  We have many clients who clearly benefit from the settlement and we are documenting their claims for compensation.  For people who are not represented by lawyers yet, we are still on request, reviewing situations and accepting retainers in cases that qualify for compensation.

THE FOLLOWING PARAGRAPHS HAVE NOT BEEN UPDATED SINCE SETTLEMENT APPROVAL WAS GIVEN:

We have heard from a number of angry clients and others who will receive little or no compensation.  We also have clients who are happy with the settlement and that they will be compensated finally even where the compensation is not believed to be adequate.  If you are not happy with the settlement do speak out and the court will consider what you have to say.  Our firm is not in a position to take a position for or against the settlement as we have many clients who have conflicting views and we can not represent some to the detriment of others. We can not say that we are happy with this settlement. It is not as good a settlement as the one for users of Celebrex or Bextra who suffered similar harm.  We encourage our unhappy clients to get independent advice and legal representation if they wish to oppose the settlement.  To be fair to the class action lawyers it is their view that this is a good settlement which was the best that could be done given the nature of the case and the impact of the Australian court decision. Had Merck been willing to negotiate earlier there is no doubt that the settlement would be better.  In the US the pressure of numerous cases being reached for trial put pressure on Merck to settle much sooner and for a lot more money for each claim.

Further to the Australian trial decision and appeal,  the Australian High Court in May 2012 denied an attempt to appeal the dismissal of the claims and so that is the end for the Australian Vioxx case.  Australia’s laws are similar to Canada’s and the Australian decision has a major legal impact on us.  The decision gives much ammunition to the class action lawyers who argue that the Canadian settlement is a “very good one”. All of this will be considered by the Ontario and Quebec courts when the court approval application is heard. We do expect approval to be given to the settlement and after that claims will be processed.  It is likely that the first settlement money will be received by claimants in early 2013.

Several months ago the NBC TV show Dateline NBC taped an episode including an interview with Pam Cottingham, one of our Vioxx clients, who suffered a serious stroke at age 43 following Vioxx use.  That show was aired on Sunday March 4, 2012 and shows how a drug like Vioxx can still be approved. You can see the entire show below in six parts with the portion dealing with our client and the Vioxx settlement in Canada in Part One.

Visit msnbc.com for breaking news, world news, and news about the economy

We continue to act for everyone in our existing group of clients to get compensation but we are only taking on new cases which qualify under the Canadian settlement.